Reduced sensitivity of the SARS-CoV-2 Lambda variant to monoclonal antibodies and neutralizing antibodies induced by infection and vaccination

References

• Wu F, Zhao S, Yu B, et al. A new coronavirus associated with human respiratory disease in China. Nature. 2020 Mar;579(7798):265–269.
   PubMed Web of Science ®Google Scholar
• WHO Coronavirus (COVID-19) Dashboard. Available from: https://covid19.who.int/.
   Google Scholar
• Lythgoe MP, Middleton P. Ongoing clinical trials for the management of the COVID-19 pandemic. Trends Pharmacol Sci. 2020 Jun;41(6):363–382.
   PubMed Web of Science ®Google Scholar
• Gao J, Tian Z, Yang X. Breakthrough: Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies. Biosci Trends. 2020 Mar 16;14(1):72–73.
   PubMed Web of Science ®Google Scholar
• Lund LC, Kristensen KB, Reilev M, et al. Adverse outcomes and mortality in users of non-steroidal anti-inflammatory drugs who tested positive for SARS-CoV-2: A danish nationwide cohort study. PLoS Med. 2020 Sep;17(9):e1003308.
   PubMed Web of Science ®Google Scholar
• Libster R, Perez Marc G, Wappner D, et al. Early high-titer plasma therapy to Prevent severe covid-19 in older adults. N Engl J Med. 2021 Feb 18;384(7):610–618.
   PubMed Web of Science ®Google Scholar
• O’Brien MP, Forleo-Neto E, Musser BJ, et al. Subcutaneous REGEN-COV antibody combination to Prevent covid-19. N Engl J Med. 2021 Aug 4;385:e70.
   PubMed Web of Science ®Google Scholar
• Copin R, Baum A, Wloga E, et al. The monoclonal antibody combination REGEN-COV protects against SARS-CoV-2 mutational escape in preclinical and human studies. Cell. 2021 Jul 22;184(15):3949–3961 e11.
   PubMed Web of Science ®Google Scholar
• An EUA for sotrovimab for treatment of COVID-19. Med Lett Drugs Ther. 2021 Jun 28;63(1627):97–xx98.
   PubMed Web of Science ®Google Scholar
• Fathizadeh H, Afshar S, Masoudi MR, et al. SARS-CoV-2 (covid-19) vaccines structure, mechanisms and effectiveness: A review. Int J Biol Macromol. 2021 Aug 14;188:740–750.
   PubMed Web of Science ®Google Scholar
• Tracking SARS-CoV-2 variants. Available from: https://www.who.int/en/activities/tracking-SARS-CoV-2-variants/.
   Google Scholar
• Yao H, Song Y, Chen Y, et al. Molecular architecture of the SARS-CoV-2 virus. Cell. 2020 Oct 29;183(3):730–738 e13.
   PubMed Web of Science ®Google Scholar
• Forni G, Mantovani A. Covid-19 commission of accademia nazionale dei lincei R. COVID-19 vaccines: where we stand and challenges ahead. Cell Death Differ. 2021 Feb;28(2):626–639.
   PubMed Web of Science ®Google Scholar
• Piccoli L, Park YJ, Tortorici MA, et al. Mapping neutralizing and immunodominant sites on the SARS-CoV-2 Spike receptor-binding domain by structure-guided high-resolution serology. Cell. 2020 Nov 12;183(4):1024–1042 e21.
   PubMed Web of Science ®Google Scholar
• Davies NG, Abbott S, Barnard RC, et al. Estimated transmissibility and impact of SARS-CoV-2 lineage B.1.1.7 in england. Science. 2021 Apr 9;372(6538):eabg3055.
   PubMed Web of Science ®Google Scholar
• Ong SWX, Chiew CJ, Ang LW, et al. Clinical and virological features of SARS-CoV-2 variants of concern: a retrospective cohort study comparing B.1.1.7 (alpha), B.1.315 (beta), and B.1.617.2 (delta). Clin Infect Dis. 2021 Aug 23.
   Web of Science ®Google Scholar
• Wang P, Nair MS, Liu L, et al. Antibody resistance of SARS-CoV-2 variants B.1.351 and B.1.1.7. Nature. 2021 May;593(7857):130–135.
   PubMed Web of Science ®Google Scholar
• Edara VV, Norwood C, Floyd K, et al. Infection- and vaccine-induced antibody binding and neutralization of the B.1.351 SARS-CoV-2 variant. Cell Host Microbe. 2021 Apr 14;29(4):516–521 e3.
   PubMed Web of Science ®Google Scholar
• Harvey WT, Carabelli AM, Jackson B, et al. SARS-CoV-2 variants, spike mutations and immune escape. Nat Rev Microbiol. 2021 Jul;19(7):409–424.
   PubMed Web of Science ®Google Scholar
• Supasa P, Zhou D, Dejnirattisai W, et al. Reduced neutralization of SARS-CoV-2 B.1.1.7 variant by convalescent and vaccine sera. Cell. 2021 Apr 15;184(8):2201–2211 e7.
   PubMed Web of Science ®Google Scholar
• Liu J, Liu Y, Xia H, et al. BNT162b2-elicited neutralization of B.1.617 and other SARS-CoV-2 variants. Nature. 2021 Aug;596(7871):273–275.
   PubMed Web of Science ®Google Scholar
• Liu C, Ginn HM, Dejnirattisai W, et al. Reduced neutralization of SARS-CoV-2 B.1.617 by vaccine and convalescent serum. Cell. 2021 Aug 5;184(16):4220–4236 e13.
   PubMed Web of Science ®Google Scholar
• Sharun K, Tiwari R, Dhama K, et al. Emerging SARS-CoV-2 variants: impact on vaccine efficacy and neutralizing antibodies. Hum Vaccin Immunother. 2021 Jun 23;17:1–4.
   PubMed Web of Science ®Google Scholar
• Akkiz H. Implications of the novel mutations in the SARS-CoV-2 genome for transmission, disease severity, and the vaccine development. Front Med (Lausanne. 2021;8:636532.
   PubMed Web of Science ®Google Scholar
• Lambda Variant Report. Available from: https://outbreak.info/situation-reports/lambda?loc=PER&selected=Worldwide&overlay=false.
   Google Scholar
• Tchesnokova V, Kulasekara H, Larson L, et al. Acquisition of the L452R mutation in the ACE2-binding interface of Spike protein triggers recent massive expansion of SARS-CoV-2 variants. J Clin Microbiol. 2021 Aug 11;59:JCM0092121.
   Web of Science ®Google Scholar
• Motozono C, Toyoda M, Zahradnik J, et al. SARS-CoV-2 spike L452R variant evades cellular immunity and increases infectivity. Cell Host Microbe. 2021 Jul 14;29(7):1124–1136 e11.
   PubMed Web of Science ®Google Scholar
• Li Q, Wu J, Nie J, et al. The impact of mutations in SARS-CoV-2 Spike on viral infectivity and antigenicity. Cell. 2020 Sep 3;182(5):1284–1294 e9.
   PubMed Web of Science ®Google Scholar
• Wang R, Chen J, Gao K, et al. Vaccine-escape and fast-growing mutations in the United Kingdom, the United States, Singapore, Spain, India, and other COVID-19-devastated countries. Genomics. 2021 Jul;113(4):2158–2170.
   PubMed Web of Science ®Google Scholar
• Pan HX, Liu JK, Huang BY, et al. Immunogenicity and safety of a severe acute respiratory syndrome coronavirus 2 inactivated vaccine in healthy adults: randomized, double-blind, and placebo-controlled phase 1 and phase 2 clinical trials. Chin Med J (Engl). 2021 Apr 28;134(11):1289–1298.
   PubMed Web of Science ®Google Scholar
• Zhu F, Jin P, Zhu T, et al. Safety and immunogenicity of a recombinant adenovirus type-5-vectored COVID-19 vaccine with a homologous prime-boost regimen in healthy participants aged 6 years and above: a randomised, double-blind, placebo-controlled, phase 2b trial. Clin Infect Dis. 2021 Sep 22.
   Web of Science ®Google Scholar
• Zhu FC, Guan XH, Li YH, et al. Immunogenicity and safety of a recombinant adenovirus type-5-vectored COVID-19 vaccine in healthy adults aged 18 years or older: a randomised, double-blind, placebo-controlled, phase 2 trial. Lancet. 2020 Aug 15;396(10249):479–488.
   PubMed Web of Science ®Google Scholar
• Zhu FC, Li YH, Guan XH, et al. Safety, tolerability, and immunogenicity of a recombinant adenovirus type-5 vectored COVID-19 vaccine: a dose-escalation, open-label, non-randomised, first-in-human trial. Lancet. 2020 Jun 13;395(10240):1845–1854.
   PubMed Web of Science ®Google Scholar
• Yang R, Deng Y, Huang B, et al. A core-shell structured COVID-19 mRNA vaccine with favorable biodistribution pattern and promising immunity. Signal Transduct Target Ther. 2021 May 31;6(1):213.
   PubMed Web of Science ®Google Scholar
• Zhang NN, Li XF, Deng YQ, et al. A thermostable mRNA vaccine against COVID-19. Cell. 2020 Sep 3;182(5):1271–1283 e16.
   PubMed Web of Science ®Google Scholar
• Nie J, Li Q, Wu J, et al. Quantification of SARS-CoV-2 neutralizing antibody by a pseudotyped virus-based assay. Nat Protoc. 2020 Nov;15(11):3699–3715.
   PubMed Web of Science ®Google Scholar
• Li Q, Nie J, Wu J, et al. SARS-CoV-2 501Y.V2 variants lack higher infectivity but do have immune escape. Cell. 2021 Apr 29;184(9):2362–2371 e9.
   PubMed Web of Science ®Google Scholar
• Deng W, Wang Y, Liu Z, et al. Hemi: a toolkit for illustrating heatmaps. PLoS One. 2014;9(11):e111988.
   PubMed Web of Science ®Google Scholar
• Messali S, Bertelli A, Campisi G, et al. A cluster of the new SARS-CoV-2 B.1.621 lineage in Italy and sensitivity of the viral isolate to the BNT162b2 vaccine. J Med Virol. 2021 Jul 30.
   Web of Science ®Google Scholar
• Hoffmann M, Kleine-Weber H, Schroeder S, et al. SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and Is blocked by a clinically proven protease inhibitor. Cell. 2020 Apr 16;181(2):271–280 e8.
   PubMed Web of Science ®Google Scholar
• Park JE, Li K, Barlan A, et al. Proteolytic processing of Middle East respiratory syndrome coronavirus spikes expands virus tropism. Proc Natl Acad Sci U S A. 2016 Oct 25;113(43):12262–12267.
   PubMed Web of Science ®Google Scholar
• Mykytyn AZ, Breugem TI, Riesebosch S, et al. SARS-CoV-2 entry into human airway organoids is serine protease-mediated and facilitated by the multibasic cleavage site. Elife. 2021 Jan 4;10:e64508.
   PubMed Web of Science ®Google Scholar
• Felgenhauer U, Schoen A, Gad HH, et al. Inhibition of SARS-CoV-2 by type I and type III interferons. J Biol Chem. 2020 Oct 9;295(41):13958–13964.
   PubMed Web of Science ®Google Scholar
• Hoffmann M, Mosbauer K, Hofmann-Winkler H, et al. Chloroquine does not inhibit infection of human lung cells with SARS-CoV-2. Nature. 2020 Sep;585(7826):588–590.
   PubMed Web of Science ®Google Scholar
• Kimura I, Kosugi Y, Wu J, et al. SARS-CoV-2 Lambda variant exhibits higher infectivity and immune resistance. bioRxiv. 2021 2021-01-01 00:00:00.
   Google Scholar
• Tada T, Zhou H, Dcosta BM, et al. SARS-CoV-2 Lambda variant remains susceptible to neutralization by mRNA vaccine-elicited antibodies and convalescent serum. bioRxiv. 2021 2021-01-01 00:00:00.
   Google Scholar
• Nie J, Xie J, Liu S, et al. Three epitope-distinct human antibodies from RenMab mice neutralize SARS-CoV-2 and cooperatively minimize the escape of mutants. Cell Discov. 2021 Jul 20;7(1):1–11.
   PubMed Web of Science ®Google Scholar
• Deng X, Garcia-Knight MA, Khalid MM, et al. Transmission, infectivity, and neutralization of a spike L452R SARS-CoV-2 variant. Cell. 2021 Jun 24;184(13):3426–3437 e8.
   PubMed Web of Science ®Google Scholar
• McCallum M, Bassi J, De Marco A, et al. SARS-CoV-2 immune evasion by the B.1.427/B.1.429 variant of concern. Science. 2021 Aug 6;373(6555):648–654.
   PubMed Web of Science ®Google Scholar
• Cao Y, Su B, Guo X, et al. Potent neutralizing antibodies against SARS-CoV-2 identified by high-throughput single-cell sequencing of convalescent patients’ B cells. Cell. 2020 Jul 9;182(1):73–84 e16.
   PubMed Web of Science ®Google Scholar
• Gazit S, Shlezinger R, Perez G, et al. Comparing SARS-CoV-2 natural immunity to vaccine-induced immunity: reinfections versus breakthrough infections. medRxiv. 2021 2021-01-01 00:00:00.
   PubMedGoogle Scholar
• Schmidt F, Weisblum Y, Rutkowska M, et al. High genetic barrier to escape from human polyclonal SARS-CoV-2 neutralizing antibodies. bioRxiv. 2021 2021-01-01 00:00:00.
   Google Scholar
• Wang Z, Muecksch F, Schaefer-Babajew D, et al. Naturally enhanced neutralizing breadth against SARS-CoV-2 one year after infection. Nature. 2021 Jul;595(7867):426–431.
   PubMed Web of Science ®Google Scholar
• Khoury DS, Cromer D, Reynaldi A, et al. Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection. Nat Med. 2021 Jul;27(7):1205–1211.
   PubMed Web of Science ®Google Scholar
• Liu H, Wei P, Zhang Q, et al. The Lambda variant of SARS-CoV-2 has a better chance than the Delta variant to escape vaccines. bioRxiv. 2021 Aug 26.
   Google Scholar
• Acevedo ML, Alonso-Palomares L, Bustamante A, et al. Infectivity and immune escape of the new SARS-CoV-2 variant of interest lambda. medRxiv. 2021 2021-01-01 00:00:00.
   PubMedGoogle Scholar